At the news
? NEUTRALIMPACT 3/10 8-K filed Aug 6, 2026 at 17:30 ET
Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presentation highlights ~66% YoY revenue growth in Q2 2026, a ~$99M quarterly revenue >10% above guidance, ~56% gross margin from cost of sales, and ~$304M cash runway into 2H 2028. The filing is a routine business update with no material new events beyond the existing pipeline and commercial progress.
- 2Q26 revenue ~$99M, >10% above guidance, ~66% YoY growth
- Cash position ~$304M as of June 30, 2026, runway into 2H 2028
- ~56% gross margin from cost of sales in 2Q26, 50% YTD
- >95 authorized treatment centers in North America
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access